BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bansal S, Singal AK, McGuire BM, Anand BS. Impact of all oral anti-hepatitis C virus therapy: A meta-analysis. World J Hepatol 2015; 7(5): 806-813 [PMID: 25914781 DOI: 10.4254/wjh.v7.i5.806] [Cited by in CrossRef: 41] [Cited by in F6Publishing: 35] [Article Influence: 5.9] [Reference Citation Analysis]
Number Citing Articles
1 Du L, Tang H. miRNA antagonism and direct-acting antivirals: could this be a novel combination treatment against HCV? Future Virology 2016;11:753-6. [DOI: 10.2217/fvl-2016-0109] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
2 Trabut JB, Barrault C, Charlot H, Carmona D, Bourdel A, Benslimane M, François M, Kini-Matondo W, Causse R, Roudot-Thoraval F, Hézode C. Integrated Care for the Use of Direct-acting Antivirals in Patients With Chronic Hepatitis C and Substance Use Disorder. J Addict Med 2018;12:346-52. [PMID: 29702515 DOI: 10.1097/ADM.0000000000000415] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 4.7] [Reference Citation Analysis]
3 Schwambach KH, Farias MR, Neto GB, Blatt CR. Cost and Effectiveness of the Treatment of Chronic Hepatitis C in Brazil: Real-World Data. Value Health Reg Issues 2020;23:49-54. [PMID: 32702649 DOI: 10.1016/j.vhri.2020.05.002] [Reference Citation Analysis]
4 Moore MS, Bocour A, Laraque F, Winters A. A Surveillance-Based Hepatitis C Care Cascade, New York City, 2017. Public Health Rep 2018;133:497-501. [PMID: 29902392 DOI: 10.1177/0033354918776641] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
5 Wedemeyer H, Craxí A, Zuckerman E, Dieterich D, Flisiak R, Roberts SK, Pangerl A, Zhang Z, Martinez M, Bao Y, Calleja JL. Real-world effectiveness of ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in patients with hepatitis C virus genotype 1 or 4 infection: A meta-analysis. J Viral Hepat 2017;24:936-43. [PMID: 28480525 DOI: 10.1111/jvh.12722] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 6.4] [Reference Citation Analysis]
6 Jeffrey AW, Huang Y, de Boer WB, Adams LA, MacQuillan G, Speers D, Joseph J, Jeffrey GP. Improved Hepascore in hepatitis C predicts reversal in risk of adverse outcome. World J Hepatol 2017; 9(19): 850-856 [PMID: 28740596 DOI: 10.4254/wjh.v9.i19.850] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
7 Moore MS, Bocour A, Jordan L, McGibbon E, Varma JK, Winters A, Laraque F. Development and Validation of Surveillance-Based Algorithms to Estimate Hepatitis C Treatment and Cure in New York City. J Public Health Manag Pract 2018;24:526-32. [PMID: 29227418 DOI: 10.1097/PHH.0000000000000688] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Bertino G, Ragusa R, Corsaro LS, Frazzetto E, Messina V, Inguscio L, Lai C, Maglia M, Nunnari A, Caponnetto P. Improvement of health-related quality of life and psychological well-being after HCV eradication with direct-acting antiviral agents. Real life setting data of an Italian cohort valued by Hepatitis Quality of Life Questionnaire (HQLQv2). Health Psychol Res 2020;8:9450. [PMID: 33553794 DOI: 10.4081/hpr.2020.9450] [Reference Citation Analysis]
9 Hermetet C, Dubois F, Gaudy-Graffin C, Bacq Y, Royer B, Gaborit C, D'Alteroche L, Desenclos JC, Roingeard P, Grammatico-Guillon L. Continuum of hepatitis C care in France: A 20-year cohort study. PLoS One 2017;12:e0183232. [PMID: 28850623 DOI: 10.1371/journal.pone.0183232] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
10 Gupta E, Agarwala P, Kumar G, Maiwall R, Sarin SK. Point -of -care testing (POCT) in molecular diagnostics: Performance evaluation of GeneXpert HCV RNA test in diagnosing and monitoring of HCV infection. J Clin Virol 2017;88:46-51. [PMID: 28160728 DOI: 10.1016/j.jcv.2017.01.006] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 8.2] [Reference Citation Analysis]
11 Zheng K, Wu SZ, Lv YW, Pang P, Deng L, Xu HC, Shi YC, Chen XY. Carvacrol inhibits the excessive immune response induced by influenza virus A via suppressing viral replication and TLR/RLR pattern recognition. J Ethnopharmacol 2021;268:113555. [PMID: 33152425 DOI: 10.1016/j.jep.2020.113555] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Webster R, Moore MS, Bocour A, Johnson N, Winters A. Health Department Efforts to Increase Hepatitis C RNA Testing Among People Appearing Out of Care: Comparison of Outreach Approaches, New York City, 2017. Public Health Rep 2020;135:823-30. [PMID: 32886566 DOI: 10.1177/0033354920952068] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Benítez-Gutiérrez L, de Mendoza C, Baños I, Duca A, Arias A, Treviño A, Requena S, Citores MJ, Cuervas-Mons V. Drug-Induced Lung Injury in a Liver Transplant Patient Treated With Sofosbuvir. Transplant Proc 2016;48:2515-8. [PMID: 27742338 DOI: 10.1016/j.transproceed.2016.08.026] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
14 Huang P, Wang Y, Yue M, Ge Z, Xia X, Jeyarajan AJ, Holmes JA, Yu R, Zhu C, Yang S, Lin W, Chung RT. The risk of hepatitis C virus recurrence in hepatitis C virus-infected patients treated with direct-acting antivirals after achieving a sustained virological response: A comprehensive analysis. Liver Int 2021. [PMID: 34051040 DOI: 10.1111/liv.14976] [Reference Citation Analysis]
15 Abraham P. Treatment for hepatitis C virus infection in India: Promising times. Indian J Med Microbiol 2016;34:273-4. [PMID: 27514946 DOI: 10.4103/0255-0857.188312] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
16 Refaat B, El-Shemi AG, Ashshi AM, Mahamid EW, Al-Qadi NM. Pegylated Interferon-α Modulates Liver Concentrations of Activin-A and Its Related Proteins in Normal Wistar Rat. Mediators Inflamm 2015;2015:414207. [PMID: 26236109 DOI: 10.1155/2015/414207] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
17 Ali S, Ur-Rehman T, Ali M, Haque S, Rasheed F, Lougher E, Nawaz MS, Paudyal V. Improving access to the treatment of hepatitis C in low- and middle-income countries: evaluation of a patient assistance programme. Int J Clin Pharm 2021;43:958-68. [PMID: 33247820 DOI: 10.1007/s11096-020-01202-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
18 Ye D, Bao Z, Yu Y, Han Z, Yu Y, Xu Z, Ma W, Yuan Y, Zhang L, Xu Y, Ma T, Liu S, Gao X, Yan G, Huang Q, Wang X, Hua B, Yang F, Li Y, Cai B. Inhibition of cardiomyocyte differentiation of human induced pluripotent stem cells by Ribavirin: Implication for its cardiac developmental toxicity. Toxicology 2020;435:152422. [PMID: 32112805 DOI: 10.1016/j.tox.2020.152422] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
19 Wu SY, Faire B, Gane E. Drug Induced Pneumonitis Secondary to Treatment with Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir (VIEKIRA PAK®) for Chronic Hepatitis C: Case Report of an Unexpected Life-Threatening Adverse Reaction. Case Rep Med 2017;2017:4895736. [PMID: 28408931 DOI: 10.1155/2017/4895736] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
20 Tong MJ, Chang PW, Huynh TT, Rosinski AA, Tong LT. Adverse events associated with ribavirin in sofosbuvir-based therapies for patients with chronic hepatitis C: A community practice experience. J Dig Dis 2016;17:113-21. [PMID: 26749171 DOI: 10.1111/1751-2980.12313] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
21 Kamiyama N, Soma R, Hidano S, Watanabe K, Umekita H, Fukuda C, Noguchi K, Gendo Y, Ozaki T, Sonoda A, Sachi N, Runtuwene LR, Miura Y, Matsubara E, Tajima S, Takasaki T, Eshita Y, Kobayashi T. Ribavirin inhibits Zika virus (ZIKV) replication in vitro and suppresses viremia in ZIKV-infected STAT1-deficient mice. Antiviral Res 2017;146:1-11. [PMID: 28818572 DOI: 10.1016/j.antiviral.2017.08.007] [Cited by in Crossref: 57] [Cited by in F6Publishing: 42] [Article Influence: 11.4] [Reference Citation Analysis]
22 Alimohammadi A, Holeksa J, Thiam A, Truong D, Conway B. Real-world Efficacy of Direct-Acting Antiviral Therapy for HCV Infection Affecting People Who Inject Drugs Delivered in a Multidisciplinary Setting. Open Forum Infect Dis 2018;5:ofy120. [PMID: 29992173 DOI: 10.1093/ofid/ofy120] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 5.8] [Reference Citation Analysis]
23 Pham TM, Tran SC, Lim YS, Hwang SB. Hepatitis C Virus-Induced Rab32 Aggregation and Its Implications for Virion Assembly. J Virol 2017;91:e01662-16. [PMID: 27852857 DOI: 10.1128/JVI.01662-16] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
24 Christenson JC, Manaloor JJ. Hepatitis A, B, and C. Pediatr Rev. 2016;37:426-438. [PMID: 27694120 DOI: 10.1542/pir.2015-0075] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
25 Ascha MS, Ascha ML, Hanouneh IA. Management of immunosuppressant agents following liver transplantation: Less is more. World J Hepatol 2016; 8(3): 148-161 [PMID: 26839639 DOI: 10.4254/wjh.v8.i3.148] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
26 Madan S, Patel SR, Rahgozar K, Saeed O, Murthy S, Vukelic S, Sims DB, Shin JJ, Goldstein DJ, Jorde UP. Utilization rates and clinical outcomes of hepatitis C positive donor hearts in the contemporary era. The Journal of Heart and Lung Transplantation 2019;38:907-17. [DOI: 10.1016/j.healun.2019.06.023] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
27 Castro R, Perazzo H, Grinsztejn B, Veloso VG, Hyde C. Chronic Hepatitis C: An Overview of Evidence on Epidemiology and Management from a Brazilian Perspective. Int J Hepatol. 2015;2015:852968. [PMID: 26693356 DOI: 10.1155/2015/852968] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
28 Carty PG, Fawsitt CG, Gillespie P, Harrington P, O'Neill M, Smith SM, Teljeur C, Ryan M. Population-Based Testing for Undiagnosed Hepatitis C: A Systematic Review of Economic Evaluations. Appl Health Econ Health Policy 2021. [PMID: 34870793 DOI: 10.1007/s40258-021-00694-w] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Talal AH, Dumas EO, Bauer B, Rejman RM, Ocque A, Morse GD, Lucic D, Cloherty GA, King J, Zha J, Zhang H, Cohen DE, Shulman N, Pawlotsky JM, Hézode C. Hepatic Pharmacokinetics and Pharmacodynamics With Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir Treatment and Variable Ribavirin Dosage. J Infect Dis 2018;217:474-82. [PMID: 29228392 DOI: 10.1093/infdis/jix495] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
30 Rattanaburee T, Junking M, Panya A, Sawasdee N, Songprakhon P, Suttitheptumrong A, Limjindaporn T, Haegeman G, Yenchitsomanus PT. Inhibition of dengue virus production and cytokine/chemokine expression by ribavirin and compound A. Antiviral Res 2015;124:83-92. [PMID: 26542647 DOI: 10.1016/j.antiviral.2015.10.005] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
31 Davison J, O'Shea A, Waterbury N, Villalvazo Y. Examining Hepatitis, A and B Vaccination, and HBV Reactivation Monitoring During Direct-Acting Antiviral Therapy for Hepatitis C. J Community Health 2018;43:1124-7. [PMID: 29846860 DOI: 10.1007/s10900-018-0530-0] [Reference Citation Analysis]
32 Zhu X, Wang M, Liu M, Yu X, Huang P. Efficacy and safety of direct-acting antivirals for treatment-naive patients with genotype 1 hepatitis C virus infection. Per Med 2019. [PMID: 31591934 DOI: 10.2217/pme-2018-0121] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
33 Suwanthawornkul T, Anothaisintawee T, Sobhonslidsuk A, Thakkinstian A, Teerawattananon Y. Efficacy of Second Generation Direct-Acting Antiviral Agents for Treatment Naïve Hepatitis C Genotype 1: A Systematic Review and Network Meta-Analysis. PLoS One 2015;10:e0145953. [PMID: 26720298 DOI: 10.1371/journal.pone.0145953] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 6.1] [Reference Citation Analysis]
34 Mera J, Vellozzi C, Hariri S, Carabin H, Drevets DA, Miller A, Reilley B, Essex W, Gahn D, Lyons L, Leston J, Ward JW. Identification and Clinical Management of Persons with Chronic Hepatitis C Virus Infection — Cherokee Nation, 2012–2015. MMWR Morb Mortal Wkly Rep 2016;65:461-6. [DOI: 10.15585/mmwr.mm6518a2] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 6.0] [Reference Citation Analysis]
35 Ahmed R, Kareem R, Venkatesan N, Botleroo RA, Ogeyingbo OD, Bhandari R, Gyawali M, Elshaikh AO. Sofosbuvir/Velpatasvir - A Promising Treatment for Chronic Hepatitis C Virus Infection. Cureus 2021;13:e17237. [PMID: 34540464 DOI: 10.7759/cureus.17237] [Reference Citation Analysis]
36 Pérez-Pitarch A, Guglieri-López B, Ferriols-Lisart R, Merino-Sanjuán M. A model-based meta-analysis of sofosbuvir-based treatments in chronic hepatitis C patients. Int J Antimicrob Agents 2016;47:184-94. [PMID: 26915476 DOI: 10.1016/j.ijantimicag.2015.12.008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
37 Patel K, Zickmund SL, Jones H, Reid A, Calgaro L, Otero A, Coppler T, Rogal SS. Determinants of Hepatitis C Treatment Adherence and Treatment Completion Among Veterans in the Direct Acting Antiviral Era. Dig Dis Sci 2019;64:3001-12. [PMID: 30903364 DOI: 10.1007/s10620-019-05590-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]